LightIntegra Technology got its start in the Canadian Blood Services R&D labs through the efforts of research scientist Dr. Elisabeth Maurer. Her years of research on platelet function led to a breakthrough discovery about the temperature response of platelets. Dr. Maurer recognized the opportunity to use this discovery — coupled with advances in laser and optics technology — to address a market need to provide a safe, quick and simple diagnostic test for microparticles, platelet quality and function.
The company was incorporated in November 2008 in order to commercialize the ThromboLUX® technology. The company successfully closed three rounds of financing during the development of the commercial version of ThromboLUX.